Horizon Pharma (NASDAQ:HZNP) has been given a $17.00 target price by research analysts at Cantor Fitzgerald in a report released on Monday. The brokerage presently has a “buy” rating on the biopharmaceutical company’s stock. Cantor Fitzgerald’s target price points to a potential upside of 10.03% from the stock’s current price.
HZNP has been the topic of a number of other reports. Piper Jaffray Companies set a $18.00 target price on Horizon Pharma and gave the stock a “buy” rating in a report on Sunday, September 10th. Stifel Nicolaus reaffirmed a “buy” rating and issued a $20.00 target price on shares of Horizon Pharma in a report on Sunday, October 22nd. ValuEngine raised Horizon Pharma from a “hold” rating to a “buy” rating in a report on Monday, October 16th. Cowen reaffirmed a “buy” rating on shares of Horizon Pharma in a report on Thursday, September 28th. Finally, Goldman Sachs Group began coverage on Horizon Pharma in a report on Thursday, September 28th. They issued a “buy” rating and a $16.00 target price on the stock. One research analyst has rated the stock with a sell rating, three have given a hold rating and eleven have given a buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus target price of $18.75.
Horizon Pharma (HZNP) traded up $0.08 during mid-day trading on Monday, hitting $15.45. The stock had a trading volume of 1,556,200 shares, compared to its average volume of 1,382,950. The stock has a market cap of $2,540.00, a P/E ratio of -5.08, a P/E/G ratio of 0.73 and a beta of 1.30. Horizon Pharma has a 52-week low of $9.45 and a 52-week high of $18.31. The company has a current ratio of 1.64, a quick ratio of 1.52 and a debt-to-equity ratio of 1.89.
Several hedge funds have recently modified their holdings of HZNP. Advantage Investment Management LLC increased its position in shares of Horizon Pharma by 164.8% in the 3rd quarter. Advantage Investment Management LLC now owns 7,874 shares of the biopharmaceutical company’s stock valued at $100,000 after acquiring an additional 4,900 shares during the period. Bank of Montreal Can increased its position in shares of Horizon Pharma by 16.3% in the 2nd quarter. Bank of Montreal Can now owns 9,809 shares of the biopharmaceutical company’s stock valued at $116,000 after acquiring an additional 1,378 shares during the period. Sheaff Brock Investment Advisors LLC increased its position in shares of Horizon Pharma by 5.0% in the 2nd quarter. Sheaff Brock Investment Advisors LLC now owns 10,500 shares of the biopharmaceutical company’s stock valued at $125,000 after acquiring an additional 500 shares during the period. Family Management Corp acquired a new position in shares of Horizon Pharma in the 2nd quarter valued at $131,000. Finally, Brown Advisory Inc. acquired a new position in shares of Horizon Pharma in the 3rd quarter valued at $145,000. 86.58% of the stock is currently owned by institutional investors and hedge funds.
About Horizon Pharma
Horizon Pharma Public Limited Company is a biopharmaceutical company. The Company is focused on identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs. As of December 31, 2016, the Company marketed 11 medicines through its orphan, rheumatology and primary care business units.
